Inhibition of c-MET upregulates PD-L1 expression in lung adenocarcinoma

Non-small cell lung cancer (NSCLC) patients with c-MET dysregulation may benefit from c-MET inhibitors therapy as inhibition of c-MET activity has emerged as a therapeutic approach against this disease. Although several c-MET inhibitors have been evaluated in multiple clinical trials in lung cancer,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am J Cancer Res
Main Authors: Sun, Xian, Li, Chia-Wei, Wang, Wei-Jan, Chen, Mei-Kuang, Li, Hui, Lai, Yun-Ju, Hsu, Jennifer L, Koller, Paul B, Chan, Li-Chuan, Lee, Pei-Chih, Cheng, Fang-Ju, Yam, Clinton, Chen, Gong-Yan, Hung, Mien-Chie
Formato: Artigo
Idioma:Inglês
Publicado em: e-Century Publishing Corporation 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7061748/
https://ncbi.nlm.nih.gov/pubmed/32195027
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados